Screening for congenital coagulation disorders.

Research output: Contribution to journalArticle

Abstract

A thorough screening procedure to diagnose congenital coagulation disorders must start from a careful collection of the personal and family clinical history, followed by a two-step laboratory screening. The first step is aimed at detecting the most frequent and well established causes of hemorrhage by a simple battery of laboratory tests such as bleeding time, platelet count, prothrombin time and activated partial thromboplastin time. The second step is to be performed in case of a past history of bleeding, but normal first-step laboratory screening and is aimed at detecting the less frequent abnormalities of hemostasis such as factor XIII, antiplasmin, platelet factor 3, von Willebrand factor, tissue plasminogen activator and dysfibrinogenemia, to which the first-step screening tests are not sensitive.

Original languageEnglish
Pages (from-to)327-332
Number of pages6
JournalLa Ricerca in Clinica e in Laboratorio
Volume19
Issue number4
Publication statusPublished - Oct 1989

Fingerprint

Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Coagulation
Screening
Platelet Factor 3
Hemorrhage
Factor XIII
Antifibrinolytic Agents
Bleeding Time
Partial Thromboplastin Time
Prothrombin Time
von Willebrand Factor
Tissue Plasminogen Activator
Hemostasis
Platelet Count
Exercise Test
Thromboplastin
Prothrombin
Platelets

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Screening for congenital coagulation disorders. / Tripodi, A.

In: La Ricerca in Clinica e in Laboratorio, Vol. 19, No. 4, 10.1989, p. 327-332.

Research output: Contribution to journalArticle

@article{0706897315ce444caa1e0613883d07c4,
title = "Screening for congenital coagulation disorders.",
abstract = "A thorough screening procedure to diagnose congenital coagulation disorders must start from a careful collection of the personal and family clinical history, followed by a two-step laboratory screening. The first step is aimed at detecting the most frequent and well established causes of hemorrhage by a simple battery of laboratory tests such as bleeding time, platelet count, prothrombin time and activated partial thromboplastin time. The second step is to be performed in case of a past history of bleeding, but normal first-step laboratory screening and is aimed at detecting the less frequent abnormalities of hemostasis such as factor XIII, antiplasmin, platelet factor 3, von Willebrand factor, tissue plasminogen activator and dysfibrinogenemia, to which the first-step screening tests are not sensitive.",
author = "A. Tripodi",
year = "1989",
month = "10",
language = "English",
volume = "19",
pages = "327--332",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Screening for congenital coagulation disorders.

AU - Tripodi, A.

PY - 1989/10

Y1 - 1989/10

N2 - A thorough screening procedure to diagnose congenital coagulation disorders must start from a careful collection of the personal and family clinical history, followed by a two-step laboratory screening. The first step is aimed at detecting the most frequent and well established causes of hemorrhage by a simple battery of laboratory tests such as bleeding time, platelet count, prothrombin time and activated partial thromboplastin time. The second step is to be performed in case of a past history of bleeding, but normal first-step laboratory screening and is aimed at detecting the less frequent abnormalities of hemostasis such as factor XIII, antiplasmin, platelet factor 3, von Willebrand factor, tissue plasminogen activator and dysfibrinogenemia, to which the first-step screening tests are not sensitive.

AB - A thorough screening procedure to diagnose congenital coagulation disorders must start from a careful collection of the personal and family clinical history, followed by a two-step laboratory screening. The first step is aimed at detecting the most frequent and well established causes of hemorrhage by a simple battery of laboratory tests such as bleeding time, platelet count, prothrombin time and activated partial thromboplastin time. The second step is to be performed in case of a past history of bleeding, but normal first-step laboratory screening and is aimed at detecting the less frequent abnormalities of hemostasis such as factor XIII, antiplasmin, platelet factor 3, von Willebrand factor, tissue plasminogen activator and dysfibrinogenemia, to which the first-step screening tests are not sensitive.

UR - http://www.scopus.com/inward/record.url?scp=0024743456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024743456&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 327

EP - 332

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 4

ER -